MedTrace Logo

The ENIGMA Study: Eastern Inflammatory Bowel Disease Gut Microbiota

NCT03462875 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 532

Last updated 2023-02-08

No results posted yet for this study

Summary

The incidence of inflammatory bowel diseases, (IBD) including Crohn's disease (CD) and ulcerative colitis (UC), is increasing in the developing world. Our recent Asia-Pacific population-based study in 8 Asian countries and Australia has demonstrated that Hong Kong and China have amongst the highest disease incidences in Asia while Australia has the equal highest incidence of these diseases in the world.

The ENIGMA project comprises three main enteric microbiome domains of central importance to Crohn's disease. Two specific organisms which may play a critical role in disease pathogenesis, including the candidate protective bacterium, and the novel pathogenic candidate, will be characterized and studied in detail. Microbial findings will be related to a detailed assessment of environmental factors that permit microbial changes or expression.

Conditions

  • Crohn Disease

Sponsors & Collaborators

  • University of Melbourne

    collaborator OTHER

  • The University of Queensland

    collaborator OTHER

  • Sun Yat-sen University

    collaborator OTHER

  • Kunming Medical University

    collaborator OTHER

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Siew Chien Ng, PhD · Chinese University of Hong Kong

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-29
Primary Completion
2021-02-28
Completion
2024-02-28

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03462875 on ClinicalTrials.gov